Effectiveness of a Mobile-based HIV Prevention Intervention Involving Incentive Policy for Doctors in Liangshan, China
6. juni 2022 opdateret af: Yu Sun, Peking University
Effectiveness of a Mobile-based HIV Prevention Intervention for Rural and Low-income Population Involving Incentive Policy for Doctors in Liangshan, China: a Randomized Controlled Trial Protocol
This study will be carried out in Liangshan Yi Autonomous Prefecture, Sichuan province, China, using a single-blinded randomized controlled trial design to measure the effects of a mobile-based HIV-related information intervention on group HIV/AIDS prevention.
Village doctors will be responsible for sending the HIV-related health education information to the participants.
The aim of this study is to develop a generalizable, effective, acceptable, and convenient mobile-based information intervention model to improve HIV-related knowledge, attitudes, practices, and health outcomes in poverty-stricken areas in China and measure the impact of incentive policies on the work of village doctors in Liangshan, China.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
4000
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Guoen Liu
- Telefonnummer: 13901359157
- E-mail: gordonliu@nsd.pku.edu.cn
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- aged 18 years or older
- has mobile phone with internet service
- has and use WeChat and TikTok account regularly
- willing to provide informed consent
- speak Mandarin Chinese or Yi ethnic group's language
Exclusion Criteria:
- diagnosed with psychiatric disorders
- diagnosed with severe cognitive impairment
- diagnosed with severe physical disabilities
- has already attended or is currently attending another intervention program
- plan on moving out of Liangshan in the 18-month study period
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Mobile-based intervention with standardized incentive
Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive standardized compensation for performing the work.
|
HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
|
|
Eksperimentel: Mobile-based intervention with performance-based incentive
Participants will receive biweekly messages containing HIV-related educational modules from village doctors who will receive performance-based compensation for performing the work.
|
HIV/AIDS awareness-raising and behavior-related cyclic messages will be delivered by the village doctors on a biweekly basis for 18 months.
village doctors in Intervention A and B will receive different types of monetary compensation.
Doctors in Intervention A will receive standardized compensation for completing their assigned tasks.
Doctors in Intervention B will receive performance-based compensation whose amount depends on how well the participants perform on the follow-up questionnaires.
|
|
Ingen indgriben: Control without intervention
Participants will not receive the mobile-based intervention
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
HIV-related knowledge improvement
Tidsramme: 18 months
|
Result will be obtained by calculating weighted scores for the indicators in the HIV Knowledge Questionnaire 18 (HIV-KQ-18) to represent the participants' and their family members' level of knowledge measured by the baseline and follow-up questionnaires.
The HIV-KQ-18 is a self-administered 18-item questionnaire; the possible scores range from 0 to 18, with 0-9 representing low HIV-related knowledge and 10-18 representing high HIV-related knowledge.
|
18 months
|
|
Comparison of the effectiveness of different financial compensations
Tidsramme: 18 months
|
The research team will compare the two interventions to determine what type of financial reward, standardized compensation or participant performance-based compensation, is more effective at incentivizing village doctors to deliver and promote the intervention content.
|
18 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effectiveness of secondary knowledge transmission: HIV-related knowledge improvement of the participants' family members
Tidsramme: 18 months
|
The research team will examine the path of secondary knowledge transmission to the participants' family members by having the family members complete the HIV Knowledge Questionnaire 18 (HIV-KQ-18).
The HIV-KQ-18 is a self-administered 18-item questionnaire; the possible scores range from 0 to 18, with 0-9 representing low HIV-related knowledge and 10-18 representing high HIV-related knowledge.
|
18 months
|
|
Behavioral changes: condom use
Tidsramme: 18 months
|
Assess the changes in participants' condom use via the Condoms Use Self-Efficacy Scale (CUSES), a 28-item self-reporting questionnaire using a 5-point scale scoring system in which 0 represents strongly disagree and 4 represents strongly agree.
|
18 months
|
|
Behavioral changes: substance use
Tidsramme: 18 months
|
Assess the severity, frequency and change of participants' substance use via the Drug and Abuse Screening Test (DAST), a 10-item questionnaire with scores range from 0 to 10; 0-2 representing low substance use and 9-10 representing severe substance use.
|
18 months
|
|
Health outcomes: HIV prevalence
Tidsramme: 18 months
|
Will be collecting regional data on HIV prevalence through collaboration with local departments.
|
18 months
|
|
Health outcomes: mental health
Tidsramme: 18 months
|
Assessed via the use of the Primary Care Evaluation of Mental Disorders (PRIME-MD) patient questionnaire, a self-reporting questionnaire consisting of 26 yes/no questions about the presence of various symptoms of different mental disorders.
|
18 months
|
|
Health outcomes: all-cause mortality
Tidsramme: 18 months
|
Will be collecting regional data on all-cause mortality through collaboration with local departments.
|
18 months
|
|
Social factors: quality of life
Tidsramme: 18 months
|
Measured via the use of EQ-5D-3L, a questionnaire comprised of 5 questions and a visual analogue scale to assess the participants' health-related quality of life.
Each question has three possible answers corresponding to three levels of perceived problems.
Level 1 indicates no problem and level 3 indicates extreme problems.
The visual analogue scale is numbered from 0 to 100, with 0 representing "the worst health you can imagine" and 100 representing "the best health you can imagine"
|
18 months
|
|
Social factors: stigma towards HIV
Tidsramme: 18 months
|
Assessed via the use of the Internalized AIDS-Related Stigma Scale, a 6-item scale that offers a binary (yes/no) response to every item and the scores is computed as the sums of the items with 6 representing high stigmatization and 0 representing low stigmatization.
|
18 months
|
|
Social factors: perception of social support
Tidsramme: 18 months
|
Assess participants' social support in the community via the use of the Medical Outcomes Study Social Support Survey (MOS-SS), a self-reporting 19-item survey.
The mean score of the 19 items will be calculated and transferred onto a 0-100 scale with higher scores indicating more support.
|
18 months
|
|
Retention of HIV-related knowledge
Tidsramme: 18 months
|
Measured by the HIV Knowledge Questionnaire 18 (HIV-KQ-18).
The research team will ask all participants to complete the questionnaire every six months after the intervention period and compare their new scores with their previous score to examine their ability to recall information from the educational modules.
The HIV-KQ-18 is a self-administered 18-item questionnaire; the possible scores range from 0 to 18, with 0-9 representing low HIV-related knowledge and 10-18 representing high HIV-related knowledge.
|
18 months
|
|
Feasibility: participants' use of social media applications
Tidsramme: 18 months
|
Feasibility of the intervention will be calculated by dividing the number of people who can use WeChat and TikTok by the total number of people living in the area.
|
18 months
|
|
Level of engagement
Tidsramme: 18 months
|
Measured by an original engagement and attendance scale.
Participants will choose from a range 1 to 6, with 1 representing non-engaging and 6 representing highly engaging.
|
18 months
|
|
Study's acceptability and satisfaction
Tidsramme: 18 months
|
Assessed via an original 15-item questionnaire with rating scales (6 is Highly Satisfied and 1 is Highly Unsatisfied).
Participants will be asked to rate and provide feedback on the intervention's content and method, including the effectiveness of the HIV-related knowledge modules, the time and method of information delivery, village doctors' attitude and competence, the design of the entire experimental intervention process, and more.
|
18 months
|
|
Cost-effectiveness of the intervention:
Tidsramme: 18 months
|
Data on the intervention's direct and indirect costs will be collected.
Direct cost involves labor costs, research-related travel expenses, and village doctors' and participants' financial compensations.
Indirect cost consists of the expenses on cell phone internet data.
The date will then be used to evaluate the cost-effectiveness of both interventions.
|
18 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Guoen Liu, Peking University
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Forventet)
1. januar 2023
Primær færdiggørelse (Forventet)
1. december 2024
Studieafslutning (Forventet)
1. december 2025
Datoer for studieregistrering
Først indsendt
24. juli 2021
Først indsendt, der opfyldte QC-kriterier
14. august 2021
Først opslået (Faktiske)
20. august 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
9. juni 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
6. juni 2022
Sidst verificeret
1. juni 2022
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- Langsomme virussygdomme
- HIV-infektioner
- Erhvervet immundefektsyndrom
Andre undersøgelses-id-numre
- 71833001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .